Ultrasound‐based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: A systematic review and meta‐analysis

Corlan O. Adebajo, Jayant A. Talwalkar, John J. Poterucha, W. Ray Kim, Michael R. Charlton – 5 December 2011 – Ultrasound‐based transient elastography (TE) is a promising noninvasive alternative to liver biopsy for the detection of hepatic fibrosis due to recurrent hepatitis C virus (HCV) after liver transplantation (LT). However, its overall test performance in various settings remains unknown.

A 7‐gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection

Nicole T. do O, Dennis Eurich, Petra Schmitz, Maximilian Schmeding, Christoph Heidenhain, Marcus Bahra, Christian Trautwein, Peter Neuhaus, Ulf P. Neumann, Hermann E. Wasmuth – 5 December 2011 – Fibrosis recurrence after liver transplantation (LT) for hepatitis C virus (HCV) is a universal event and strongly determines a patient's prognosis. The recipient risk factors for fibrosis recurrence are still poorly defined. Here we assess a genetic risk score as a predictor of fibrosis after LT.

Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipients

Monica Franciosi, Lucio Caccamo, Paolo De Simone, Antonio Daniele Pinna, Giovanni Giuseppe Di Costanzo, Riccardo Volpes, Vincenzo Scuderi, Paolo Strignano, Patrizia Boccagni, Patrizia Burra, Antonio Nicolucci, for the TWINS I Study Group – 5 December 2011 – To date, there is still a lack of instruments for specifically assessing the impact of anti–hepatitis B virus prophylaxis after liver transplantation (LT) on health‐related quality of life (HRQOL) and treatment satisfaction.

Is a mandatory intensive care unit stay needed after liver transplantation? Feasibility of fast‐tracking to the surgical ward after liver transplantation

C. Burcin Taner, Darrin L. Willingham, Ilynn G. Bulatao, Timothy S. Shine, Prith Peiris, Klaus D. Torp, Juan Canabal, Justin H. Nguyen, David J. Kramer – 5 December 2011 – The continuation of hemodynamic, respiratory, and metabolic support for a variable period after liver transplantation (LT) in the intensive care unit (ICU) is considered routine by many transplant programs. However, some LT recipients may be liberated from mechanical ventilation shortly after the discontinuation of anesthesia.

Exercise capacity and muscle strength in patients with cirrhosis

Jacqueline C. Jones, Jeff S. Coombes, Graeme A. Macdonald – 5 December 2011 – Exercise capacity and muscle strength are predictors of outcome in a number of clinical populations. Advanced liver disease is a catabolic state, and patients often have muscle wasting. However, the relationships between exercise capacity, strength, and outcomes for patients undergoing liver transplantation are poorly understood.

Cumulative risk of cardiovascular events after orthotopic liver transplantation

Mazen Albeldawi, Ashish Aggarwal, Surabhi Madhwal, Jacek Cywinski, Rocio Lopez, Bijan Eghtesad, Nizar N. Zein – 5 December 2011 – As survival after orthotopic liver transplantation (OLT) improves, cardiovascular (CV) disease has emerged as the leading cause of non–graft‐related deaths. The aims of our study were to determine the cumulative risk of CV events after OLT and to analyze predictive risk factors for those experiencing a CV event after OLT. We identified all adult patients who underwent OLT at our institution for end‐stage liver disease between October 1996 and July 2008.

Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: Comparison of prophylactic oral ganciclovir and oral valganciclovir

Ashley N. Bedel, Trina S. Hemmelgarn, Rohit Kohli – 5 December 2011 – Cytomegalovirus (CMV) is the most common viral infection after solid organ transplantation (SOT). Safe and effective prophylactic regimens that decrease its incidence after SOT are essential for long‐term graft survival. Although valganciclovir is not Food and Drug Administration–approved for CMV prophylaxis in liver transplant recipients, postmarketing studies have shown valganciclovir to be as effective as ganciclovir in high‐risk adult patients undergoing SOT.

Reconstruction of inferior right hepatic veins in living donor liver transplantation using right liver grafts

Shin Hwang, Tae‐Yong Ha, Chul‐Soo Ahn, Deok‐Bog Moon, Ki‐Hun Kim, Gi‐Won Song, Dong‐Hwan Jung, Gil‐Chun Park, Jung‐Man Namgoong, Sung‐Won Jung, Sam‐Youl Yoon, Kyu‐Bo Sung, Gi‐Young Ko, Byungchul Cho, Kyoung Won Kim, Sung‐Gyu Lee – 5 December 2011 – Because revascularization of the inferior right hepatic vein (IRHV) is a major component of right liver graft (RLG) reconstruction, we assessed the surgical techniques and clinical outcomes of IRHV reconstruction so that we could formulate practical guidelines for standardized procedures.

Economic model of a birth cohort screening program for hepatitis C virus

Lisa J. McGarry, Vivek S. Pawar, Hemangi R. Panchmatia, Jaime L. Rubin, Gary L. Davis, Zobair M. Younossi, James C. Capretta, Michael J. O'Grady, Milton C. Weinstein – 2 December 2011 – Recent research has identified high hepatitis C virus (HCV) prevalence among older U.S. residents who contracted HCV decades ago and may no longer be recognized as high risk. We assessed the cost‐effectiveness of screening 100% of U.S.

Variants in ABCB1, TGFB1, and XRCC1 genes and susceptibility to viral hepatitis A infection in Mexican Americans

Lyna Zhang, Ajay Yesupriya, Dale J. Hu, Man‐huei Chang, Nicole F. Dowling, Renée M. Ned, Venkatachalam Udhayakumar, Mary Lou Lindegren, Yury Khudyakov – 2 December 2011 – Hepatitis A vaccination has dramatically reduced the incidence of hepatitis A virus (HAV) infection, but new infections continue to occur.

Subscribe to